AcclaimIP-ad

Match Document Document Title
8790658 Antigen-adjuvant compositions and methods  
Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions,...
8790660 Vaccine against Ehrlichia canis  
Vaccine and/or immunogenic compositions that comprise an effective immunizing amount of an antigen from E. canis are described. In addition, methods of immunizing a subject against E. canis by...
8790662 Methods for treating refractory infections in neutropenic individuals  
The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection....
8784829 Lawsonia intracellularis vaccines  
The present invention relates to polynucleotide sequences encoding novel Lawsonia intracellularis polypeptides. It also relates to DNA fragments, recombinant plasmid DNA and live recombinant...
8784842 Allelic exchange mutagenesis in Map  
Particular aspects provide efficient allelic exchange methods to generate directed mutations within genes of slow-growing stains of mycobacteria (e.g., Mycobacterium avium subsp. paratuberculosis...
8784825 Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC  
Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying...
8784826 Multiple vaccination including serogroup C meningococcus  
Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an...
8778349 Modification of intrinsically disordered sequences for the preparation of vaccines  
The intrinsically disordered sequences—or “intrinsically disorded sequences” or IDSeq—proteins should be flexible to ensure a controlled interaction between proteins. In the development of the...
8778384 Compositions and methods for encapsulating vaccines for the oral vaccination and boostering of fish and other animals  
The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly...
8778348 Trypanosoma antigens, vaccine compositions, and related methods  
The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma...
8779088 Vaccine for the treatment of Mycobacterium related disorders  
The invention relates to genes and proteins involved in the sporulation of Mycobacteria and the use thereof in the technical fields of immunology and medicine. A vaccine comprising spore forming...
8771698 Modulation of UL24 interactions with protein targets and uses thereof for inhibition of herpesvirus infection  
Methods and uses for the treatment of herpesvirus infection based on the inhibition of the interaction between herpesvirus UL24 and non-muscle myosin type IIa (NM2a) are described.
8771707 Botulinum neurotoxin E receptors and uses thereof  
An isolated polypeptide comprising an amino acid sequence selected from amino acids 506-582 of SV2A, wherein position 573 is N and is glycosylated, or amino acids 449-525 of SV2B, wherein position...
8765148 1C31 nanoparticles  
The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13...
8765366 Clinical correlates  
A method of assessing an intracellular pathogen infection and/or monitoring an intracellular pathogen infection in an individual comprises determining whether the individual has (a) T-cells that...
8765139 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals  
The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated...
8765146 Adenoviral vector-based malaria vaccines  
The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably...
8765171 Methods and compositions for liposomal formulation of antigens and uses thereof  
The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These...
8758766 Modified Streptococcus pneumoniae pneumolysin (PLY) polypeptides  
This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against...
8758771 Bacterial virulence factors and uses thereof  
The invention relates to, in part, secreted proteins of bacterial pathogens and methods for their use. More specifically, the invention provides in part several new common secreted proteins for...
8759310 Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8  
The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based...
8758762 Method for preparing recombinant antigen complex using rotavirus nanoparticle  
Disclosed are a construct for expressing a rotavirus antigen complex loaded with a heterologous virus epitope, a vaccine composition containing the rotavirus antigen complex, a virus-like particle...
8758759 Transmucosal administration of aggregated antigens  
The present invention relates to modulation of the immune response in a mammal. In particular, the invention relates to methods of inducing oral tolerance and systemic immunity in a mammal. The...
8758760 Oral vaccine  
The present invention provides an oral vaccine against a bacterial infectious disease (e.g., typhoid fever, cholera, or dysentery). The oral vaccine of the present invention is a capsule...
8758763 Archaeal polar lipid aggregates for administration to animals  
The invention provides non-replicating compositions, and methods for the delivery of these compositions containing pharmaceuticals, biologically relevant molecules, and/or antigens to the host, by...
8758761 Combination therapies for treating type 1 diabetes  
In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.
8758773 Vaccine candidates against Johne's disease  
A composition and method for immunizing a mammal infected with Mycobacterium are disclosed. The genes gcpE, pstA, kdpC, papA2, impA, umaA1, fabG2_2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, and...
8758772 Peptides and methods for the detection of lyme disease antibodies  
The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens. The peptide compositions comprise polypeptide sequences...
8753643 Spray dried compositions and methods of use  
Provided herein are insoluble particles that include polypeptides. The polypeptides may have immunogenicity that is greater than the immunogenicity of the same polypeptides when they are not...
8753642 Method of treating hepatitis C virus  
A method of treating or inhibiting hepatitic C virus (HCV). The method comprises administering an effective amount of at least one pokeweed antiviral protein (PAP) mutant alone or in combination...
8753651 Capsular polysaccharide solubilisation and combination vaccines  
Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide,...
8748567 Method for delivery across the blood brain barrier  
The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The...
8747856 Antigen binding fragments of an antibody for use in treating or diagnosing ocular diseases  
The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon...
8747861 Multimeric multiepitope influenza vaccines  
The present invention relates to multimeric multi-epitope peptide-based vaccines. In particular, the present invention relates to the use of multimeric multi-epitope peptide-based vaccines...
8748173 Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof  
The present invention provides monoclonal antibodies which are highly specific for Bacillus spores. Also provided are peptides derived from those monoclonal antibodies. Both the antibodies and...
8747843 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor  
One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one...
8747863 Vaccine for shigella  
Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection....
8741306 Kidney specific tumor vaccine directed against kidney tumor antigen G-250  
This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker....
8741314 Multivalent meningococcal polysaccharide-protein conjugate vaccine  
The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of...
8741298 APOE immunotherapy  
The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use...
8742088 Nucleic acids encoding antibodies or portions thereof comprising a heterologous T cell epitope and their use in modulating T cell responses  
The present invention provides a nucleic acid which comprises a non-specific promoter and at least one sequence that encodes a polypeptide that has at least one heterologous T cell epitope therein...
8741313 Polypeptide vaccine and vaccination strategy against mycobacterium  
A vaccine is provided wherein a polypeptide or combination of peptides from M. tuberculosis is administered to a subject to elicit an immune response. The polypeptide vaccine is administered as...
8741876 Therapeutic agent for ulcerative colitis  
A method for treating a patient having ulcerative colitis, by administering a drug which containing an effective amount of tetracyclines is provided. The drug may also contain penicillins and/or...
8741301 Method for generation of RNA virus  
The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus.
8735542 HIV-1 clade a consensus sequences, antigens, and transgenes  
The present invention relates to consensus nucleotide and protein sequences for HIV-1 Clade A antigens, and to nucleotide and protein sequences for Clade A antigens from circulating HIV-1 field...
8734781 Method of preventing early Lawsonia intracellularis infections  
The present invention relates inter alia to the use of a combination of a vaccine against Lawsonia intracellularis and an anti-Lawsonia antibiotic for the prevention or reduction of early,...
8734812 Neisserial antigenic peptides  
This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such...
8734804 Treatment of myelosuppression  
Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by...
8734807 Preventing and curing Schistosomiasis mansoni by inhibiting Trk receptors on female Schistosoma  
Schistosomiasis mansoni is caused by flukes called Schistosoma(es) that enters the human body through the skin in Schistosoma infested waters. The Schistosomes travel from the skin into human...
8734813 Multivalent meningococcal polysaccharide-protein conjugate vaccine  
The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of...